Mutagenesis-induced, large fitness variations with an invariant arenavirus consensus genomic nucleotide sequence by Grande-Pérez, Ana et al.
JOURNAL OF VIROLOGY, Aug. 2005, p. 10451–10459 Vol. 79, No. 16
0022-538X/05/$08.000 doi:10.1128/JVI.79.16.10451–10459.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Mutagenesis-Induced, Large Fitness Variations with an Invariant
Arenavirus Consensus Genomic Nucleotide Sequence
Ana Grande-Pe´rez,1† Gema Go´mez-Mariano,1 Pedro R. Lowenstein,2 and Esteban Domingo1*
Centro de Biologı´a Molecular “Severo Ochoa” (CSIC-UAM), Cantoblanco, E-28049 Madrid, Spain,1 and Department of Medicine,
Department of Molecular and Medical Pharmacology, and Gene Therapeutics Research Institute, Cedars-Sinai
Medical Center, and Department of Medicine, University of California, Los Angeles, California2
Received 28 February 2005/Accepted 9 May 2005
Enhanced mutagenesis may result in RNA virus extinction, but the molecular events underlying this process
are not well understood. Here we show that 5-fluorouracil (FU)-induced mutagenesis of the arenavirus
lymphocytic choriomeningitis virus (LCMV) resulted in preextinction populations whose consensus genomic
nucleotide sequence remained unaltered. Furthermore, fitness recovery passages in the absence of FU, or
alternate virus passages in the presence and absence of FU, led to profound differences in the capacity of
LCMV to produce progeny, without modification of the consensus genomic sequence. Molecular genetic
analysis failed to produce evidence of hypermutated LCMV genomes. The results suggest that low-level
mutagenesis to enrich the viral population with defector, interfering genomes harboring limited numbers of
mutations may mediate the loss of infectivity that accompanies viral extinction.
Mutagenic agents administered alone or in combination
with antiviral inhibitors can drive RNA virus populations to
extinction (4, 18, 20, 21, 41, 42, 46, 48, 50, 51, 53, 65, 67, 72, 77,
79; reviewed in references 6, 27, 28, 31, and 39). Loss of
infectivity has been interpreted as an irreversible transition
that occurs when template copying fidelity falls below a critical
value termed the error threshold. Such a transition has been
termed virus entry into error catastrophe, or lethal mutagen-
esis (50), and its existence has been supported by several the-
oretical studies (5, 31, 60, 83). In agreement with this concept,
analysis of the mutant spectra of virus populations on their way
to extinction has shown 2- to 17-fold increases in mutation
frequencies, calculated among components of the mutant spec-
tra, as well as increases in Shannon entropy (a measure of the
different types of sequences present in a mutant spectrum) to
nearly maximal values (that is, each component of the mutant
spectrum showed a unique sequence) (reviewed in references
27 and 28).
The prototypic arenavirus lymphocytic choriomeningitis vi-
rus (LCMV) (12, 63, 64) showed extreme sensitivity to 5-flu-
orouracil (FU)-induced mutagenesis (41, 72) compared with
other RNA viruses subjected to comparable doses of the mu-
tagen (79). The extreme sensitivity of LCMV to FU offered an
opportunity to analyze the capacity of LCMV to regain infec-
tivity following FU mutagenesis as well as the modification of
genomic nucleotide sequence variations as the virus moves
toward or away from the error threshold and to explore the
possible dominance of hypermutated genomes in the transition
to extinction. The results reveal a remarkable capacity of
LCMV populations to modify their fitness level while main-
taining an invariant consensus sequence. Multiple molecular
clones were analyzed to define a sequence at nucleotides 470 to
550 within the intergenic region of genomic segment L. A
number of standard and mutated oligonucleotide primers have
failed to produce evidence of hypermutated viral sequences in
the L polymerase gene. The results suggest that limited mu-
tagenesis may be sufficient to drive LCMV close to the error
threshold and that LCMV can rapidly regain fitness in the
absence of a mutagen. The invariance of the consensus
genomic sequence, associated with the movements toward and
away from the error threshold, suggests a decisive participation
of the mutant spectrum in determining infectivity levels and
supports a lethal defection model for virus extinction through
enhanced mutagenesis.
MATERIALS AND METHODS
Cells and virus. Baby hamster kidney cells (BHK-21) were grown in Dulbec-
co’s modified Eagle’s medium (DMEM) with 5% fetal calf serum (FCS) as
described previously (79). Vero cells were maintained in DMEM supplemented
with 3% FCS and 2% L-glutamine. LCMV strain Armstrong (ARM) 53b is a
triple plaque-purified clone of Armstrong CA 1371, passaged four times in
BHK-21 cells (10, 23, 30, 62, 73, 80, 82). For the present experiments, a stock
virus (LCMV p0) was prepared by infecting 1  107 BHK-21 cells with LCMV
at a multiplicity of infection (MOI) of 0.01 PFU per cell (41) (LCMV ARM 53b
was kindly supplied by P. Borrow).
Virus infections. Semiconfluent (2.8  106 cells in 100-mm-diameter dishes
[Falcon]) monolayers of BHK-21 were infected with 0.01 PFU of LCMV ARM
53b per cell in 5 ml of DMEM supplemented with 10% FCS, 10% tryptose
phosphate broth, 2% L-glutamine, 0.52% glucose, and 50 g/ml gentamicin.
Viral supernatants were harvested 48 h postinfection, clarified by centrifugation
at 2,500 rpm for 30 min at 4°C, and stored at 80°C. Supernatants were titrated
on Vero cell monolayers under a semisolid agar medium, as described elsewhere
(3). Viral yields usually were 108 PFU/ml.
Serial passages of LCMV ARM 53b were carried out by infecting control (D)
or FU-treated (F) cell monolayers with the corresponding supernatants of the
previous infection. For infections carried out with a virus obtained following a D
passage, 2.8  106 BHK-21 cells were infected with about 3  104 PFU of
LCMV, whereas for infections with a virus derived from an F passage virus, the
input was103 PFU of LCMV. Virus supernatants and cells were harvested 48 h
postinfection. To obtain preextinction virus populations, semiconfluent BHK-21
monolayers (15 182-cm2 flasks with 1.6  107 cells per flask) were infected at an
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MOI of 0.01 PFU/cell and incubated for 48 h in 10 ml of infection medium (with
100 g/ml of FU) per flask. No specific LCMV sequences could be amplified and
no infectivity (10 PFU/ml) obtained from cell culture supernatants after a
second passage in 100 g/ml FU, even after 25-fold concentration with a Cen-
tricon Plus-20 Biomax-100 (Millipore) filter. Virus titers are means of three
titrations; standard deviations never exceeded 10% of the mean.
Drug treatment. Preparation of FU stock solutions, BHK-21 cell viability
assays, and infections in the presence of the mutagenic analogue were performed
as previously described (41, 79). LCMV was considered extinguished when no
reverse transcriptase PCR (RT-PCR)-amplifiable material and no infectivity
(10 PFU/ml) could be detected after three blind passages of the undiluted viral
population in BHK-21 cells in standard culture medium in the absence of mu-
tagens.
RNA extraction, RT-PCR, nucleotide sequencing, molecular cloning, and cal-
culation of mutant-spectrum complexity. RNA was extracted from supernatants
of infected cell cultures by using Trizol (Invitrogen) according to the manufac-
turer’s protocol. RNAs were amplified by two-step RT-PCR using ThermoScript
reverse transcriptase (Invitrogen) and a reverse (antisense) primer (http://www
.cbm.uam.es/mkfactory.esdomain/webs/CBMSO/plt_LineasInvestigacion.aspx
?IdObjeto17) at 60°C for 45 min, followed by PCR with Pfu DNA polymerase
(Promega). As a control to confirm that an excess of template was being ampli-
fied, 1/10 of the initial amount of template RNA was processed in parallel and
yielded a positive amplification band (4, 41). cDNAs either were purified with a
Wizard PCR purification kit (Promega) or were subjected to agarose gel elec-
trophoresis and the cDNA band extracted from the gel using a QIAEX II gel
extraction kit (QIAGEN). Purified cDNA was sequenced using Big Dye chem-
istry (ABI, Perkin-Elmer), and the products obtained were analyzed using an
ABI 377 automated sequencer (Perkin-Elmer). Molecular clones corresponding
to the intergenic regions of L RNA and of part of the GP-C-coding region in the
S segment (residues 247 to 759) were obtained by ligation of cDNA into the
pGEM-T Easy vector (Promega) and transformation into Escherichia coli DH5
cells. DNA from positive colonies was amplified with a TempliPhi amplification
kit (Amersham; based on rolling-circle amplification by the high-fidelity 29
DNA polymerase) by following the manufacturer’s protocol. Mutant-spectrum
complexity was calculated by scoring mutations relative to the consensus se-
quence defined by all the clones analyzed. Mutation frequencies for mutant
spectra of the GP-C-coding region were determined as the number of different
mutations (repeated mutations were counted only once) divided by the total
number of nucleotides sequenced (the length of the GP-C-coding region multi-
plied by the number of clones analyzed).
The entire LCMV genome was sequenced using the primers and the strategy
given in the supplementary material (http://www.cbm.uam.es/mkfactory.esdomain
/webs/CBMSO/plt_LineasInvestigacion.aspx?IdObjeto17). For sampling of
partial genomic sequences, three LCMV genomic regions were amplified by
RT-PCR and sequenced, as follows: in the S genomic RNA, the glycoprotein-
coding region between residues 268 and 738 was amplified using primers GP247F
(forward) and GP759R (reverse); in the nucleoprotein-coding region, residues
2244 to 2723 were amplified with primers NP2223F (forward) and NP2743R
(reverse); in the L RNA, the polymerase-coding region between nucleotides 2950
and 4240 was amplified with primers L2929F (forward) and L4260R (reverse)
(this set amplified the region corresponding to amino acids 978 to 1422, which
encompasses premotif A to motif E, including the catalytic domain of the viral
polymerase [24, 52, 87]). Consensus nucleotide sequences were determined using
entire viral RNA populations as templates, except for the L intergenic region, for
which consensus sequences were derived from the alignment of sequences from
multiple individual molecular clones. Most nucleotide sequences were determined
two or more times using different sense and antisense primers (described at http:
//www.cbm.uam.es/mkfactory.esdomain/webs/CBMSO/plt_LineasInvestigacion.aspx
?IdObjeto17). Nucleotide positions are given in the viral (genomic) sense and
refer to the consensus genomic sequence determined in the present study.
LCMV genomic nucleotide sequences were retrieved from GenBank (74–76)
(GenBank accession numbers BANKIT 691408 and AY 894816). Sequences
were compared using SEQMAN from the DNASTAR software package (Laser-
gene), and alignments were done with the GeneDoc program (K. B. Nicholas
and H. B. Nicholas, Jr., Pittsburgh Supercomputing Center, Pittsburgh, Pa.).
Computer-based predictions of RNA secondary structure were carried out using
the MFOLD program (92) with default folding.
Detection of hypermutated molecules. Conditions for reverse transcription and
PCR were set to increase the probability of amplification of putative hypermu-
tated molecules. The RT reaction was done with avian myeloblastosis virus
(AMV) reverse transcriptase (Promega) at 37°C for 45 min and then at 94°C for
5 min. This incubation temperature is that recommended for the synthesis of
first-strand cDNA using random oligonucleotide primers. One microliter of
RNA was thawed at 70°C for 3 min, and after cooling on ice, 8 pmol of reverse
primer was added and the mixture incubated at 65°C for 5 min. A mixture of 2.5
U of AMV and 7.5 U of RNAsin RNA inhibitor (Promega) was added in a final
reaction volume of 20 l. Five microliters of the first-strand reaction was used in
a touchdown PCR in a volume of 50 l with 1.25 U of Pfu DNA polymerase and
16 pmol of reverse and forward primers. The reaction conditions were as follows:
denaturation hold at 95°C for 2 min, followed by 20 cycles at 95°C for 1 min, 60°C
TABLE 1. Oligonucleotide primers with position degeneracies used in the present study
Namea Sequence (5	 to 3	) Type ofdegeneracy
Degree of
degeneracyb No. of clones
c Avg no. of mutations
per clonec
L3662F AGTTTAAGAACCCTTCCCGC 0 0 15 (R)d 2.06 
 1.83
L3662F R2 ARTTTAARAACCCTTCCCGC 2 A/G 4 NDe ND
L3662F RY2 AGTTYAARAACCCTTCCCGC 1 A/G, 1 C/T 4 ND ND
L3662F RY4 ARTTTAARAAYCCTTCYCGC 2 A/G, 2 C/T 8 9 (RY4) 1.77 
 1.39
L3662F Y5 AGTTYAAGAAYCCYTCYCGY 5 C/T 10 5 (R) 1.60 
 1.14
L3662F Y5Bis AGYYYAAGAACCCYYCCCGC 5 C/T 10 10 (RY5) 1.20 
 1.03
L3662F R5 RGTTTRRGRRCCCTTCCCGC 5 A/G 10 9 (RR4) 1.77 
 0.97
L3662F RY7 ARTTYAARAAYCCYTCYCGY 2 A/G, 5 C/T 14 NAf
L3662F RY16 RGYYYRRGRRYYYYYYYYGC 5 A/G, 11 C/T 32 NA
L4260R TGTTGAGGGTTCCACAGAGC 0 0 15 (R) 2.06 
 1.83
L4260R YR2 TGTTGARGGYTCCACAGAGC 1 A/G, 1 C/T 4 ND
L4260R R3 TGTTGARGGTTCCACRGARC 3 A/G 6 9 (FRY4) 1.66 
 1.65
L4260R R4 TGTTGRGGGTTCCRCRGRGC 4 A/G 8 5 (FY5Bis) 1.00 
 0.70
L4260R Y4 YGTYGAGGGYTCYACAGAGC 4 C/T 8 15 (F) 2.20 
 2.33
L4260R Y5 YGYYGAGGGYYCCACAGAGC 5 C/T 10 13 (FR5) 0.69 
 0.94
L4260R YR7 YGTYGARGGYTCYACRGARC 3 A/G, 4 C/T 14 NA
L4260R RY16 YRYYRRRRRYYCCRCRRRRC 11 A/G, 5 C/T 32 NA
a Forward primer L3662F and reverse primers L4260R were modified to produce a battery of degenerate primers. The types (Y  C  T; R  A  G) and total
number of degeneracies for each primer are indicated by boldfaced letters.
b Calculated by multiplying the number of degenerate positions by the number of possible nucleotides (A, G, C, or T).
c Results shown only for the FU-treated sample.
d The paired oligonucleotide used in the PCR is given in parentheses.
e ND, not determined. Amplifications using L3662F R2 and L3662F RY2 were positive using RNA from amplification of control samples (D) but negative with RNA
from FU-treated virus (F).
f NA, negative amplification (no DNA band observed) in control or FU-treated samples. All oligonucleotides yielded positive amplification of control and FU-treated
virus samples, except those that had degeneracy over 10.
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for 30 s (starting at an annealing temperature of 60°C, with a decrease of 0.5°C
per cycle), and 72°C for 2 min, and finally 10 additional cycles at an annealing
temperature of 47°C. Assuming that the more-frequent mutations induced by FU
are transitions of the types A3G and U3C (41, 65, 67, 72, 79), oligonucleotides
with different degrees of degeneracy (which should favor hybridization with
mutated templates) were synthesized. Oligonucleotides L3662F (forward) and
L4260R (reverse) were modified to produce a battery of degenerate primers to
amplify residues 3662 to 4260 of the L polymerase-coding region (Table 1). The
cDNAs synthesized were purified with a Wizard PCR purification kit (Promega),
ligated into the pGEM-T Easy vector (Promega), and used to transform E. coli
DH5; positive bacterial clones were amplified with the TempliPhi amplification
kit (Amersham). Purified cDNA and molecular clones were subjected to cycle
sequencing. Standard RNA consisted of an SP6 RNA polymerase runoff tran-
script of a molecular clone that contained the polymerase region amplified with
primers L3662F and L4260R in the genomic sense. Quantification of RNAs of
control and FU-treated virus populations was done by two-step RT-PCR with
ThermoScript RT (Invitrogen) at 60°C for 45 min, followed by a hold at 85°C for
5 min; 2 l of the first-strand reaction product was used in a 20-l reaction
mixture with the Fast Start DNA Master SYBR Green I kit (Roche) in a Light
Cycler instrument (Roche). A standard curve employed serial 10-fold dilutions of
the standard RNA from 1010 to 105 molecules. Mutation frequencies were
calculated as described above.
Nucleotide sequence accession numbers. The consensus genomic sequence
determined in the present study has been deposited in GenBank under accession
numbers AY847350 for the S genomic segment and AY847351 for the L genomic
segment.
RESULTS
Rapid FU-mediated decrease of LCMV infectivity and rapid
recovery in the absence of mutagens. Serial population pas-
sages of RNA viruses under a defined set of stable conditions
generally result in fitness gain (32, 58), and lethal mutagenesis
is less effective with high-fitness virus (67, 79). To investigate
whether loss of infectivity of LCMV upon replication in the
presence of FU was dependent on the passage number of the
virus in BHK-21 cells, LCMV was serially passaged in BHK-21
cells at an MOI of 0.01 PFU/cell in the absence of FU, as
detailed in Materials and Methods. Using virus from passage 1,
2, 4, 5, 6, 7, 8, or 9, an infection in the presence of 100 g/ml
FU resulted in 105- to 108-fold decreases in infection progeny
production, and the decrease did not show any trend with the
passage number of LCMV in BHK-21 cells (Fig. 1A).
To study whether mutagenized populations could regain the
capacity to produce progeny in the absence of FU, several
FU-treated populations were allowed to replicate in the ab-
sence of the mutagen. In the first passage without FU, the
capacity to produce progeny, which is taken as an estimate of
relative viral fitness (33, 47), was impaired. However, two to
three passages in the absence of mutagens allowed LCMV to
regain the capacity to produce progeny at levels comparable to
those of LCMV not subjected to mutagenic treatment (Fig.
1B). Two passages in the presence of FU led to virus extinc-
tion, as defined in Materials and Methods. In one case, extinc-
tion occurred despite an intervening recovery passage (Fig.
1B). A recovered preextinction population was driven to ex-
tinction by reiteration of the mutagenic process, and the pre-
extinction population that resulted from this second round of
mutagenesis could again attain the standard capacity to pro-
duce progeny (Fig. 1B). Thus, LCMV is very sensitive to FU-
induced lethal mutagenesis, but preextinction populations
maintain the potential to produce normal infectious progeny
levels in BHK-21 cells upon replication in the absence of mu-
tagen.
Fitness variations with an invariant consensus sequence. To
study whether large fluctuations in replication capacity were
associated with modification of the consensus LCMV genomic
sequence, the entire genomic nucleotide sequences of the virus
after one passage in the absence of drug (D1), the virus sub-
jected to one passage in the presence of FU (F1), and the virus
subjected to three subsequent recovery passages in the absence
of FU (F1D3) were determined (the nomenclature of LCMV
populations that defines the passage history in the presence or
absence of FU is described in the legend for Fig. 1B). No
differences in the consensus nucleotide sequence of the three
FIG. 1. Effect of repeated mutagenesis-recovery cycles on LCMV
infectivity during serial passages of LCMV ARM 53b in BHK-21 cells.
LCMV (parental LCMV ARM 53b stock p0 with 1 108 PFU/ml) was
serially passaged by infecting BHK-21 monolayers (2.8  106 cells) at
an MOI of 0.01 PFU per cell in the absence (solid lines) or presence
(dashed lines) of 100 g/ml FU. Virus supernatants were harvested at
48 postinfection, clarified by centrifugation, and titrated on Vero cell
monolayers. (A) Virus infectivity reduction following a single passage
in the presence of FU. (B) Variation of infectivity of LCMV subjected
to FU mutagenesis and recovery in the absence of FU. Passages in the
absence or presence of FU are indicated by D and F, respectively (i.e.,
F1D3F1D2 means that the parental LCMV stock p0 was subjected
successively to one passage in the presence of FU, three passages in the
absence of FU, one passage in the presence of FU, and finally two
passages in the absence of FU). Virus extinction at passages 2, 3, and
6 was confirmed by the absence of infectivity and the absence of
virus-specific RT-PCR amplification after two further passages in the
absence of drug. Procedures are detailed in Materials and Methods.
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viruses were observed. Although some differences were seen
relative to the previously published LCMV ARM 53b se-
quence (73–76), our sequence is in good agreement with the
LCMV genomic sequence deposited in GenBank with acces-
sion number AY894816. Under the standard amplification
conditions, it was not possible to determine a defined nucleo-
tide sequence (i.e., the peak pattern suggested the presence of
insertions and/or deletions) for the intergenic region of seg-
ment L (nucleotides 470 to 550). RT-PCR at a higher temper-
ature (25, 87) in 5% dimethyl sulfoxide was used to obtain
cDNA that was cloned into the pGEM-T Easy vector (Pro-
mega). The nucleotide sequences of 13 clones from viral pop-
ulations D1, F1, and F1D3 indicated a remarkable genetic
heterogeneity with G-rich and C-rich sequences. Despite this
heterogeneity, no evidence of dominance of different subpopu-
lations was obtained for viruses D1, F1, and F1D3 (Fig. 2A).
Two of the clones harbored large deletions which likely corre-
spond to stem-loop structures deleted during the amplification
or during the sequencing reaction by polymerase slippage (71,
89); however, heterogeneity in the viral RNA cannot be ex-
cluded. We have not subjected in vitro-transcribed RNA con-
taining this region to RT-PCR to assess the contribution to the
observed heterogeneity of errors during the amplification pro-
cedure. Previous studies have reported deletions in the inter-
genic regions of LCMV (75) and Lassa fever virus (87).
To further ascertain that variations in fitness were not ac-
companied by changes in the consensus genomic nucleotide
sequence, three genomic regions (nucleotides 2950 to 4240 of
the L segment, encoding amino acids 985 to 1415 of protein L;
nucleotides 268 to 738 of the S segment, encoding amino acids
62 to 220 of GP-C; and nucleotides 2247 to 2723 of the S
segment, encoding amino acids 198 to 357 of NP) were se-
quenced for viruses D1, F1, F1D1, D4, F1D3, F1D3F1, and
F1D3F1D2 (passage history depicted in Fig. 1B). Again, no
differences in consensus sequence were observed. These re-
sults show that extreme variations in fitness of an RNA virus,
even the approach of population extinction, can occur without
being reflected in any modification of the consensus genomic
nucleotide sequence.
To rule out the possibility that the invariance of the consen-
sus sequence reflected a genetically homogeneous RNA pop-
ulation, the amplified DNAs of the GP-C-coding region be-
tween residues 247 and 759 of the S segment of populations
D1, F1, and FD3 were cloned into pGEM-T, and 8 to 13
molecular clones from each population were sequenced. The
mutation frequencies for D1, F1, and FD3 were 1.4 104, 2.3
 104, and 3.9  103, respectively (basal mutation fre-
quency levels, determined with a runoff transcript, are included
in Fig. 3), indicating that despite the invariance of the consen-
sus sequence, the quasispecies contain highly heterogeneous
mutant spectra (see also Discussion).
No evidence of dominance of hypermutated genomes. We
initially hypothesized that the transition into error catastrophe
of RNA viruses could be accompanied by the synthesis of
aberrant hypermutated, nonfunctional viral genomes and that
despite being replication incompetent, such genomes could be
detected by RT-PCR amplification (41). To search for such
hypermutated genomes, we tested a collection of multiply sub-
stituted oligonucleotide primers (Table 1) by RT-PCR ampli-
fication assays using as a template RNA extracted from either
control (D) or FU-treated (F) virus populations. Using 2.6 
107 and 3.2  107 molecules for D and F populations, we
observed positive amplification only with primers with a degree
of degeneracy of 10 or lower (Table 1). The cDNA products of
some of these amplifications were cloned and several molecu-
lar clones sequenced. No evidence of hypermutated molecules
was obtained with any of the primer combinations tested. The
mutant spectra of the F population showed higher genetic
heterogeneity than those of the D population tested, but the
average number of mutations per molecule was 2, with the
exception of a single molecule whose number of mutations lies
at the limit of viral genomes previously classified as hypermu-
tated (56) (see Discussion).
For primers without degeneracy, lowering the temperature
during first-strand synthesis, followed by touchdown amplifi-
cation, allowed detection of genomes with a number of muta-
tions that remained undetected under standard, more-strin-
gent conditions of amplification. Under these new
amplification conditions, the mutation frequency for the F
population was 4.7-fold higher than the value obtained under
standard amplification conditions whereas for the D popula-
tion the mutation frequency was 2.0-fold lower (Fig. 3). Also,
for the F population, the mutation frequencies scored were
lower when any combination of degenerate oligonucleotides
was used than with standard oligonucleotides representing the
wild-type LCMV consensus sequence. Control amplifications
employing similar numbers of molecules of L RNA runoff
transcripts as those in the D and F populations indicate that
the differences in the mutation frequency values were not due
to the amplification conditions (Fig. 3). Thus, the results do not
support our initial hypothesis that hypermutated molecules
may be dominant during the transition into error catastrophe
(41). Rather, the results suggest that mutant spectra, com-
posed of genomes harboring modest numbers of fitness-de-
creasing mutations, dominate the molecular landscape in the
LCMV transition into error catastrophe, supporting a lethal
defection model for LCMV extinction (40).
DISCUSSION
Lethal mutagenesis has been approached with a number of
RNA viruses (4, 18, 19, 21, 41, 42, 46, 48, 50, 51, 53, 65, 67, 72,
77, 79) and is currently being explored as a possible new anti-
viral strategy to provide an alternative to the use of inhibitors
of viral replication (26, 35, 38). The molecular events that
mediate the critical transition into viral extinction, also termed
virus entry into error catastrophe (5, 31, 60, 83), are still poorly
understood, but such understanding may be crucial for finding
new virus-specific mutagenic agents that, in combination with
inhibitors, could lead to a clinical application. The previous
studies with LCMV documented a very high sensitivity of the
virus to FU in cell culture (41, 72) and prevention by FU of the
establishment of a persistent LCMV infection of RAG/
(deficient in the adaptive immune response) mice (72). This
latter study constituted a proof-of-principle of the potential of
mutagenesis to prevent a viral infection in vivo. Moreover,
there is evidence that the antiviral activity of the nucleoside
analogue ribavirin, currently licensed for the treatment of sev-
eral viral diseases (68, 81), might be mediated in some cases by
its mutagenic action (4, 18–21, 39, 45, 53, 66, 88).
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FIG. 2. Nucleotide sequence and predicted secondary structure of an LCMV genomic region belonging to the L intergenic region. (A) Nu-
cleotide sequence of residues 470 to 550, corresponding to the intergenic L region of clones from populations D1, F1, and F1D3. Sequences of
clones are aligned under our consensus LCMV ARM 53b; at the bottom, the sequence previously published (termed here ARM 53b*) (76) is given.
Our sequence is in agreement with a recent sequence (deposited in GenBank with accession number AY894816), determined independently of
ours. Deletions introduced for best alignment of heteropolymeric stretches are indicated by dashes. (B) Predicted secondary structure of intergenic
L residues 365 to 466 of Lassa fever virus and predicted secondary structures of residues 470 to 550 of LCMV ARM 53b, clones D1-2, F1-4, and
F1D3-4 analyzed in the present study. Procedures for nucleotide sequence determination and secondary-structure prediction are described in
Materials and Methods.
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LCMV shows higher sensitivity to FU mutagenesis than
foot-and-mouth disease virus (FMDV) in cell culture when the
two viruses are subjected to similar FU doses (41, 65, 67, 72,
79). The basis for this difference is not known, but it may relate
either to the size of the essential polymerase gene, which
occupies 62.6% and 17.4% of the total genetic information of
LCMV and FMDV, respectively; to a larger number of essen-
tial genomic sites susceptible to FU-induced mutations in
LCMV than in FMDV; or to other replicative differences be-
tween the two viruses still to be elucidated (different affinities
of the two polymerases for FU-triphosphate, etc.). The com-
parison of complete genomic LCMV sequences reported here
has indicated that neither an abrupt decrease in infectivity
associated with FU treatment nor the ensuing recovery of the
capacity to produce infectious progeny upon replication in the
absence of mutagen modified the consensus nucleotide se-
quence of the virus. Likewise, no variations were detected
among LCMV populations subjected to one or several rounds
of replication in the absence or presence of FU, or among
populations that underwent alternations between the two pas-
sage regimens. In these cases the consensus sequences ana-
lyzed involved three genomic regions, one of which was a part
of the polymerase (L) that included premotif A and motifs A
to E (11, 24, 52, 70, 86, 87). The possibility that FU, in addition
to its mutagenic activity documented by increases in mutant-
spectrum complexity, could exert some mutagenesis-indepen-
dent, inhibitory activity (i.e., directly on the viral polymerase or
indirectly through alteration of nucleotide pools, etc.) on
LCMV replication cannot be excluded. This would mean that
FU could contribute to decreases in viral load, thereby favor-
ing mutagenesis-induced extinction, as documented with
FMDV (65–67).
It could be argued that fitness variations despite an invariant
consensus sequence may occur without modification of the
mutant spectrum, simply by an increase of dominance of a
preexisting subset of genomes with the same consensus se-
quence. A static mutant spectrum is highly unlikely given the
number of LCMV progeny per cell (Fig. 1), since it would
imply mutation rates much lower than those that have been
calculated for RNA viruses (29). Low mutation rates are not
supported by the estimates of the frequencies of cytotoxic
T-lymphocyte (CTL)- and antibody-escape mutants in LCMV
populations (1, 15, 43, 49; reviewed in reference 78). Fitness
variations without modification of consensus genomic se-
quences have been reported for vesicular stomatitis virus
clones in the process of fitness recovery after bottleneck pas-
sages (59).
The L RNA intergenic region may function as a transcrip-
tion termination signal, as previously suggested for LCMV (69,
74), other arenaviruses (25, 34, 44), and the stem-loop present
in the S RNA intergenic region of LCMV (55), Pichinde virus
(7), and Lassa fever virus (8, 16). RNA secondary-structure
predictions suggest that the L RNA intergenic region of
LCMV ARM 53b forms a stem-loop stabilized by 15 GC pairs
(Fig. 3B), similar to a loop predicted for the L RNA intergenic
regions of Tacaribe and Lassa fever virus (25, 34, 44). We have
not distinguished whether the nucleotide sequence heteroge-
neity seen in the L intergenic region (Fig. 3A) corresponds to
a heterogeneity present in the LCMV used (perhaps with func-
FIG. 3. Mutation frequencies in control and FU-treated LCMV populations. RNAs from control (D) and FU-treated (F) virus populations
were copied to cDNA (residues 3662 to 4260 of the L polymerase-coding region) under standard amplification conditions (RT reaction with
ThermoScript RT at 60°C followed by Pfu DNA polymerase amplification at an annealing temperature of 59°C) or under less stringent
amplification conditions (RT reaction with AMV RT at 37°C followed by Pfu amplification in a touchdown PCR) as indicated. Combinations of
degenerate and wild-type primers are indicated (primers used are listed in Table 1, although the first letter, L, and the nucleotide position are
omitted here for simplification). As an internal control, two dilutions of an LCMV L RNA runoff transcript (St. RNA, standard RNA) with similar
numbers of molecules as the D and F virus populations were processed in parallel under both amplification conditions. Criteria for the design of
degenerate primers and RT-PCR amplification conditions are detailed in Materials and Methods.
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tional implications) or is due to the production of altered
copies during RT-PCR, or both.
Although it cannot be excluded that highly mutated or hy-
permutated RNA molecules derived from LCMV RNA may
be present during the transition to error catastrophe, attempts
using standard and multiply substituted oligonucleotide prim-
ers have failed to reveal the dominance of such genomes (Ta-
ble 1 and Fig. 3). In the amplification with primers L3662F and
L4260 RY4, one sequence was found that had nine mutations,
of which six were U3C transitions and the others were A3G,
C3A, and G3A. The mutation frequency for this molecule
relative to the consensus sequence (1.6  102) would lie
within the lower limit in the range of 3.3  102 to 1.0  101
mutations per nucleotide for the U3C (or A3G) hypermu-
tation, previously characterized in genomes of measles virus,
human parainfluenza virus 3, vesicular stomatitis virus, and
Rous-associated virus, which has been related to posttranscrip-
tional unwinding and mutagenic activities (13, 36, 54, 56, 57,
61). Hypermutated genomes have not been identified, either,
among multiple molecular clones copied from preextinction
populations of FMDV (4, 67, 79). In the FU-mediated transi-
tion to extinction of LCMV in the course of a persistent in-
fection of BHK-21 cells, decreases in viral infectivity preceded
decreases in viral RNA levels (40). The specific infectivity of
LCMV reached values 102- to 103-fold lower than those for
LCMV from parallel cultures not subjected to FU mutagenesis
(40). Similar decreases in specific infectivity were noted for
mutagenized FMDV during persistent or cytolytic infections
(4, 37, 65, 66). These quantifications of specific infectivity,
together with the complexity of mutant spectra of mutagenized
LCMV and FMDV populations (4, 37, 40, 41, 65–67, 72, 79),
suggest that rather than requiring extensive mutagenesis, virus
extinction may be mediated by the presence of defective ge-
nomes (which have been termed “defectors” in several studies
of RNA virus evolution [85, 90]). Therefore, the present evi-
dence suggests that low-activity mutagens capable of being
incorporated specifically by viral polymerases may be sufficient
to enrich the defector population to a level at which it may
interfere with standard genome replication. A likely molecular
mechanism mediating this type of interference is the effect of
multiple, low-frequency dominant-negative mutants generated
in mutagenized virus populations, an extension to an intra-
population level of the mechanisms of interference between
different viruses, well documented in classical viral genetics
(reviewed in references 2, 17, and 91). Because such interfering
genomes—due to their partial or complete defectiveness—
cannot dominate the population, no alteration of consensus
sequences is observed despite profound fitness losses. Thus,
the results reported here support a lethal defection model for
the mutagenesis-induced genetic meltdown that results in viral
extinction (40). Treatment with the mutagenic nucleoside an-
alogue ribavirin of cell cultures infected with poliovirus or
Hantaan virus resulted in decreases in infectivity that preceded
decreases in viral RNA levels (19–21, 77), again suggesting a
role of mutagenesis-induced defective genomes that maintain
their replication competence prior to detectable losses of in-
fectivity.
The results presented here underscore the relevance of mu-
tant spectra in determining virus behavior, illustrated here by
the capacity of LCMV to either decrease or increase its fitness
without any alteration of the consensus nucleotide sequence.
This observation must be added to results with several other
virus-host systems showing suppressive or modulating effects of
mutant spectra on specific types of variants with superior fit-
ness (9, 14, 22, 37, 84).
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